This search combines search strings from the content search (i.e. "Full Text", "Author", "Title", "Abstract", or "Keywords") with "Article Type" and "Publication Date Range" using the AND operator.
Beilstein J. Org. Chem. 2025, 21, 2618–2636, doi:10.3762/bjoc.21.203
Graphical Abstract
Figure 1: Structure of thiazolidinone derivatives.
Figure 2: Selected examples of commercial drugs containing the thiazolidinone core.
Scheme 1: Multicomponent reaction of benzaldehyde, rhodanine, and piperidine in ethanol leading directly to a...
Scheme 2: Substrate scope of the EDA-catalyzed Knoevenagel condensation reactions using a range of aromatic/h...
Scheme 3: Limitations of the EDA-catalyzed Knoevenagel reactions for the synthesis of rhodanine or thiazolidi...
Scheme 4: Plausible reaction mechanism for the EDA-catalyzed Knoevenagel condensation reactions.
Scheme 5: Substrate scope of the HPW-catalyzed GBB reactions.
Scheme 6: Synthesis of imidazo[1,2-a]pyridine-thiazolidinone hybrids by EDA-catalyzed Knoevenagel condensatio...
Figure 3: Overlay of predicted (red) and experimental (black) NMR spectra for compound 3n: a) 1H NMR spectra ...
Figure 4: a) Molecular structure of 3n with crystallographic labeling (50% probability displacement). b) Pers...
Scheme 7: a) Tautomeric forms of thiazolidinones and b) resonance structures for compounds 3n and 4n.
Figure 5: Molecular energy as a function of the torsion angle obtained from a relaxed dihedral scan at the M0...
Figure 6: Identification of the carbon atoms used in the theoretical study of chemical shifts. In red, easily...
Figure 7: a) Visual impressions of the solvatochromic study in various solvents (10−5 M) after excitation wit...
Scheme 8: Proposed ICT-type mechanism for the fluorescence process, adapted from ref. [89].
Figure 8: Photophysical study in aqueous solution under different pH values for compound 3n (10−5 M) at room ...
Scheme 9: Two equilibria of compound 3n in aqueous solutions, adapted from ref. [92,93].
Figure 9: Molecular fragments associated with intramolecular charge transfer states.
Figure 10: Frontier molecular orbitals of compounds 3n and 4n in three different states: protonated, deprotona...
Beilstein J. Org. Chem. 2024, 20, 628–637, doi:10.3762/bjoc.20.55
Figure 1: Selected examples of commercial drugs containing the imidazo[1,2-a]pyridine core [13].
Figure 2: Examples of application of HPW as catalyst in the synthesis of heterocyclic compounds through multi...
Scheme 1: a) Reported phosphomolybdic acid-catalyzed synthesis of imidazo[1,2-a]pyridines via GBB-3CR. b) Att...
Scheme 2: Substrate scope of the HPW-catalyzed GBB reactions using a range of aromatic/heteroaromatic aldehyd...
Scheme 3: Substrate scope of the HPW-catalyzed GBB reaction using aliphatic aldehydes. Reaction conditions: 2...
Scheme 4: Unsuccessful substrates for the HPW-catalyzed GBB-3CR for the synthesis of imidazo[1,2-a]pyridines.
Scheme 5: 10-Fold scale-up of the HPW-catalyzed GBB reaction (5.0 mmol) between 2-aminopyridine (1a), 4-nitro...
Scheme 6: Plausible reaction mechanism for the HPW-catalyzed GBB reaction.
Beilstein J. Org. Chem. 2019, 15, 2544–2551, doi:10.3762/bjoc.15.247
Figure 1: Chemical structure of solonamides and autoinducing peptides (AIP).
Scheme 1: Macrocyclization strategy based on SN2’.
Scheme 2: Chemical synthesis of the MBH adducts 2 and their carboxylic acids 3.
Scheme 3: Chemical synthesis of the linear peptidomimetics 8.
Scheme 4: Macrocyclization strategy based on SN2’ reaction to affords the solonamide analogues 9 and their ov...
Figure 2: Effect of compounds 9e and 9g at three concentrations on the hemolysis production by S. aureus ATCC...
Figure 3: Inhibition of hemolysis (%) on human red blood cells caused by S. aureus ATCC 25923 after being in ...
Figure 4: Cell viability of human fibroblast exposed to compounds 9e (A) and 9g (B) for 24 and 48 hours. The ...